Influence of the metabolic syndrome on leptin and leptin receptor in breast cancer

2011 ◽  
Vol 50 (8) ◽  
pp. 643-651 ◽  
Author(s):  
Paul A. Carroll ◽  
Laura Healy ◽  
Joanne Lysaght ◽  
Terry Boyle ◽  
John V. Reynolds ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metabolic Syndrome ◽  
Leptin Receptor ◽  
The Metabolic Syndrome

Dexamethasone decreases the autotaxin‐lysophosphatidate‐inflammatory axis in adipose tissue: implications for the metabolic syndrome and breast cancer

2018 ◽  
Vol 33 (2) ◽  
pp. 1899-1910 ◽  
Author(s):  
Guanmin Meng ◽  
Xiaoyun Tang ◽  
Zelei Yang ◽  
Yuan Yuan Zhao ◽  
Jonathan M. Curtis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
The Metabolic Syndrome

scholarly journals Prevalence of Metabolic Syndrome among Breast Cancer Survivors in East Coast of Peninsular Malaysia

2021 ◽  
Author(s):  
Mohd Razif Shahril ◽  
Syed Amirfaiz ◽  
Pei Lin Lua ◽  
Ali Nurnazahiah ◽  
Nor Syamimi Zakarai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metabolic Syndrome ◽  
Blood Glucose ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
East Coast ◽  
Fasting Blood Glucose ◽  
Peninsular Malaysia ◽  
The Metabolic Syndrome ◽  
Metabolic Syndrome Components

Abstract Background: To date, limited data are available on metabolic syndrome prevalence among breast cancer survivors in Malaysia. Therefore, this study was conducted to determine the prevalence of metabolic syndrome and abnormal metabolic syndrome components among breast cancer survivors in East Coast of Peninsular Malaysia. Methods: This cross-sectional study included 95 breast cancer survivors (age 53.7±7.6 years) who have completed main cancer treatments for ≥6 months. Cancer survivors were recruited from two main government hospitals in Kelantan and Terengganu using a purposive sampling method. Results: According to the Harmonized criteria, the metabolic syndrome prevalence was 50.5%. Among those with metabolic syndrome, the most prevalent abnormal metabolic components were triglycerides (91.2%), fasting blood glucose (79.6%) and HDL-c level (78.4%). Except for total cholesterol and LDL-c, all other metabolic syndrome components were significantly different (p<0.05) between those with and without metabolic syndrome. Significant differences between metabolic syndrome and non-metabolic syndrome groups were found for weight, BMI, waist circumference, body fat percentage and cancer stages (p<0.05). However, no significant relationship was reported between sociodemographic, clinical parameters and metabolic syndrome among breast cancer survivors in this study. Conclusions: Metabolic syndrome was highly prevalent among breast cancer survivors. It is recommended for health care professionals to closely monitor and improve the triglycerides, blood glucose and HDL-c level of the breast cancer survivors under their care to control the detrimental effect of metabolic syndrome.

scholarly journals Comorbid pathology and prognosis of breast cancer in women in menopause.

2018 ◽  
Vol 96 (1) ◽  
pp. 55-59
Author(s):  
Nailya S. Asfandiyarova ◽  
E. P. Kulikov ◽  
A. S. Skopin ◽  
A. N. Demko ◽  
A. A. Nikiforov
Keyword(s):  
Breast Cancer ◽  
Metabolic Syndrome ◽  
Arterial Hypertension ◽  
Visceral Obesity ◽  
Suppressor Cells ◽  
Cancer Prognosis ◽  
Lymph Node Status ◽  
Regional Lymph Nodes ◽  
The Metabolic Syndrome ◽  
Menopausal Women

Comorbid pathology is important in the survival of patients with breast cancer. The main aim of the present study was to investigate prognostic criteria of the 5-year survival menopausal women with breast cancer, including both the classic criteria (age, tumor size, lymph node status, hormonal status) and the presence of comorbid pathology (arterial hypertension, visceral obesity, diabetes mellitus, metabolic syndrome, immunodeficiency). A prospective cohort study included 98 patients with breast cancer (aged 63 ± 9 years, BMI 31.6 ± 4.8 kg/m2). Criteria favorable short-term (5 years) of the cancer prognosis of breast cancer in menopausal women are the size of the tumor less than 5 cm, the absence of metastases in regional lymph nodes, and the absence of the metabolic syndrome, dyslipidemia, high activity of suppressor cells. Age, anthropometric indices (BMI, waist circumference etc.), presence of arterial hypertension do not give information about the 5-year survival rate in breast cancer.

scholarly journals Prevalence of Metabolic Syndrome among Breast Cancer Survivors in East Coast of Peninsular Malaysia

2020 ◽  
Author(s):  
Mohd Razif Shahril ◽  
Syed Amirfaiz ◽  
Pei Lin Lua ◽  
Ali Nurnazahiah ◽  
Nor Syamimi Zakarai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metabolic Syndrome ◽  
Blood Glucose ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
East Coast ◽  
Fasting Blood Glucose ◽  
Peninsular Malaysia ◽  
The Metabolic Syndrome ◽  
Metabolic Syndrome Components

Abstract To date, limited data are available on metabolic syndrome prevalence among breast cancer survivors in Malaysia. Therefore, this study was conducted to determine the prevalence of metabolic syndrome and abnormal metabolic syndrome components among breast cancer survivors in East Coast of Peninsular Malaysia. This cross-sectional study included 95 breast cancer survivors (age 53.7±7.6 years) who have completed main cancer treatments for ≥6 months. Cancer survivors were recruited from two main government hospitals in Kelantan and Terengganu using a purposive sampling method. According to the Harmonized criteria, the metabolic syndrome prevalence was 50.5%. Among those with metabolic syndrome, the most prevalent abnormal metabolic components were triglycerides (91.2%), fasting blood glucose (79.6%) and HDL-c level (78.4%). Except for total cholesterol and LDL-c, all other metabolic syndrome components were significantly different (p<0.05) between those with and without metabolic syndrome. Significant differences between metabolic syndrome and non-metabolic syndrome groups were found for weight, BMI, waist circumference, body fat percentage and cancer stages (p<0.05). However, no significant relationship was reported between sociodemographic, clinical parameters and metabolic syndrome among breast cancer survivors in this study. In conclusion, metabolic syndrome was highly prevalent among breast cancer survivors. It is recommended for health care professionals to closely monitor and improve the triglycerides, blood glucose and HDL-c level of the breast cancer survivors under their care to control the detrimental effect of metabolic syndrome.

scholarly journals Minireview: Obesity and Breast Cancer: A Tale of Inflammation and Dysregulated Metabolism

2013 ◽  
Vol 27 (5) ◽  
pp. 715-725 ◽  
Author(s):  
Evan R. Simpson ◽  
Kristy A. Brown
Keyword(s):  
Breast Cancer ◽  
Metabolic Syndrome ◽  
Postmenopausal Breast Cancer ◽  
Breast Tumors ◽  
The Other ◽  
Cellular Mechanisms ◽  
Related Factors ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
The One

Abstract In addition to the spectrum of conditions known collectively as the Metabolic Syndrome, obesity is now recognized to be associated with increased risk of several cancers including colon, endometrial, and breast cancer. Obesity and carcinogenesis share 2 characteristics in common. On the one hand, they involve inflammatory pathways, and on the other hand, they involve dysregulated metabolism. In this review we focus on postmenopausal breast cancer and discuss the metabolic and cellular mechanisms whereby obesity and breast cancer are related. Because a majority of postmenopausal breast tumors are estrogen responsive, we include a discussion of the action of obesity-related factors on estrogen formation within the breast.

Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer

2007 ◽  
Vol 8 (5) ◽  
pp. 395-408 ◽  
Author(s):  
L. Vona-Davis ◽  
M. Howard-McNatt ◽  
D. P. Rose
Keyword(s):  
Breast Cancer ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
The Metabolic Syndrome

scholarly journals Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Andrew A. Davis ◽  
Virginia G. Kaklamani
Keyword(s):  
Breast Cancer ◽  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Growth Factor ◽  
Triple Negative ◽  
Growth Factor Receptor ◽  
Breast Cancers ◽  
New Paradigm ◽  
Cancer Subtypes ◽  
The Metabolic Syndrome

Triple-negative breast cancers (TNBCs) are aggressive tumors with poor prognosis compared to other breast cancer subtypes. The evidence linking TNBC with the metabolic syndrome, which consists of central obesity, insulin resistance, impaired glucose tolerance, dyslipidemia, and hypertension, has emerged from clinical studies and experiments using cell lines and mouse models. Epidemiological studies have associated abdominal obesity with increased incidence of TNBC. Additionally, insulin resistance, dyslipidemia, and hypertension are associated with increased incidence of breast cancer across all subtypes. The insulin-leptin-adiponectin axis has been implicated mechanistically in breast cancer tumorigenesis. Specifically, increased leptin and decreased adiponectin levels disrupt homeostatic signaling pathways involved in cell proliferation, survival, cell-cycle regulation, and angiogenesis. Insulin, insulin-like growth factor I (IGF-I), and epidermal growth factor receptor (EGFR) may mediate interactions between these two hormones. Further research will facilitate the development of targeted therapeutics and programs to modify lifestyle factors to modulate the insulin-leptin-adiponectin axis for TNBC.

scholarly journals Soluble Leptin Receptor and Soluble Receptor-Bound Fraction of Leptin in the Metabolic Syndrome

2003 ◽  
Vol 11 (6) ◽  
pp. 760-768 ◽  
Author(s):  
Anton Sandhofer ◽  
Markus Laimer ◽  
Christoph F. Ebenbichler ◽  
Susanne Kaser ◽  
Bernhard Paulweber ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Leptin Receptor ◽  
Soluble Receptor ◽  
The Metabolic Syndrome ◽  
Soluble Leptin Receptor
Sign in / Sign up

Export Citation Format

Share Document